 Holly Frost
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otitis Media | 14 | 2024 | 165 | 8.330 |
Why?
| | Anti-Bacterial Agents | 29 | 2024 | 1797 | 5.430 |
Why?
| | Antimicrobial Stewardship | 9 | 2024 | 117 | 3.820 |
Why?
| | Conjunctivitis | 7 | 2024 | 30 | 3.800 |
Why?
| | Gonorrhea | 5 | 2023 | 58 | 3.510 |
Why?
| | Chlamydia Infections | 5 | 2023 | 74 | 3.490 |
Why?
| | Conjunctivitis, Bacterial | 4 | 2024 | 11 | 2.890 |
Why?
| | Haemophilus influenzae | 3 | 2024 | 63 | 1.930 |
Why?
| | Practice Patterns, Physicians' | 10 | 2024 | 1301 | 1.910 |
Why?
| | Acute Disease | 12 | 2024 | 1006 | 1.800 |
Why?
| | Amoxicillin | 3 | 2024 | 30 | 1.780 |
Why?
| | Lyme Disease | 4 | 2018 | 60 | 1.670 |
Why?
| | Respiratory Tract Infections | 4 | 2022 | 394 | 1.640 |
Why?
| | Child | 35 | 2024 | 21819 | 1.470 |
Why?
| | Blastomycosis | 3 | 2024 | 10 | 1.240 |
Why?
| | Encephalitis Viruses, Tick-Borne | 2 | 2020 | 8 | 1.220 |
Why?
| | Encephalitis, Tick-Borne | 2 | 2020 | 8 | 1.210 |
Why?
| | Pharyngitis | 2 | 2018 | 26 | 1.180 |
Why?
| | Haemophilus Infections | 2 | 2024 | 42 | 1.080 |
Why?
| | Blastomyces | 3 | 2024 | 9 | 1.080 |
Why?
| | Drug Prescriptions | 2 | 2020 | 243 | 1.080 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.070 |
Why?
| | Sinusitis | 2 | 2019 | 221 | 0.990 |
Why?
| | Syphilis | 2 | 2024 | 32 | 0.950 |
Why?
| | Infant | 12 | 2024 | 9395 | 0.860 |
Why?
| | Humans | 52 | 2024 | 136765 | 0.850 |
Why?
| | Child, Preschool | 14 | 2024 | 10997 | 0.850 |
Why?
| | Chlamydia | 1 | 2023 | 10 | 0.800 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2023 | 63 | 0.780 |
Why?
| | Guideline Adherence | 3 | 2022 | 546 | 0.780 |
Why?
| | Wisconsin | 5 | 2020 | 100 | 0.740 |
Why?
| | Ambulatory Care | 2 | 2023 | 539 | 0.740 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 587 | 0.720 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 160 | 0.690 |
Why?
| | Endemic Diseases | 2 | 2018 | 32 | 0.680 |
Why?
| | Bacterial Infections | 2 | 2020 | 250 | 0.660 |
Why?
| | Methylprednisolone | 1 | 2020 | 85 | 0.640 |
Why?
| | Papillomavirus Vaccines | 1 | 2023 | 237 | 0.640 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 250 | 0.630 |
Why?
| | Adolescent | 15 | 2024 | 21382 | 0.620 |
Why?
| | Time-to-Treatment | 1 | 2021 | 204 | 0.620 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 324 | 0.610 |
Why?
| | Infectious Mononucleosis | 1 | 2018 | 10 | 0.600 |
Why?
| | Streptococcus | 1 | 2018 | 28 | 0.600 |
Why?
| | Anaplasmosis | 1 | 2018 | 1 | 0.590 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1571 | 0.580 |
Why?
| | Babesiosis | 1 | 2017 | 2 | 0.560 |
Why?
| | Primary Health Care | 4 | 2023 | 1721 | 0.550 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 16 | 0.550 |
Why?
| | Chlamydia trachomatis | 3 | 2022 | 48 | 0.540 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 213 | 0.540 |
Why?
| | Program Evaluation | 1 | 2021 | 889 | 0.540 |
Why?
| | Outpatients | 4 | 2022 | 393 | 0.540 |
Why?
| | Streptococcal Infections | 1 | 2018 | 151 | 0.510 |
Why?
| | Male | 20 | 2024 | 67311 | 0.490 |
Why?
| | Antibodies, Fungal | 1 | 2015 | 9 | 0.490 |
Why?
| | Inpatients | 1 | 2020 | 496 | 0.480 |
Why?
| | Antigens, Fungal | 1 | 2015 | 28 | 0.480 |
Why?
| | Female | 20 | 2024 | 72795 | 0.470 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 3 | 2024 | 16 | 0.470 |
Why?
| | Drug Administration Schedule | 3 | 2024 | 785 | 0.450 |
Why?
| | Retrospective Studies | 10 | 2024 | 15504 | 0.430 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.430 |
Why?
| | Genotype | 2 | 2024 | 1914 | 0.400 |
Why?
| | Weight Reduction Programs | 2 | 2024 | 116 | 0.380 |
Why?
| | Colorado | 5 | 2024 | 4515 | 0.370 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1163 | 0.370 |
Why?
| | Neisseria gonorrhoeae | 2 | 2022 | 25 | 0.360 |
Why?
| | Pediatric Obesity | 3 | 2024 | 590 | 0.360 |
Why?
| | Physicians | 1 | 2020 | 907 | 0.350 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 165 | 0.330 |
Why?
| | Electronic Health Records | 4 | 2024 | 1046 | 0.310 |
Why?
| | Inappropriate Prescribing | 2 | 2021 | 55 | 0.310 |
Why?
| | Pandemics | 3 | 2022 | 1612 | 0.300 |
Why?
| | Doxycycline | 2 | 2020 | 62 | 0.300 |
Why?
| | United States | 6 | 2024 | 14690 | 0.300 |
Why?
| | HIV Infections | 2 | 2024 | 2828 | 0.290 |
Why?
| | Antibodies, Viral | 2 | 2023 | 624 | 0.250 |
Why?
| | Mass Screening | 3 | 2024 | 1267 | 0.250 |
Why?
| | Young Adult | 5 | 2024 | 13127 | 0.240 |
Why?
| | Ambulatory Care Facilities | 3 | 2024 | 231 | 0.240 |
Why?
| | Prevalence | 2 | 2023 | 2710 | 0.230 |
Why?
| | Treatment Outcome | 3 | 2024 | 10745 | 0.230 |
Why?
| | Administration, Ophthalmic | 1 | 2024 | 15 | 0.230 |
Why?
| | Child Care | 1 | 2024 | 31 | 0.220 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 75 | 0.220 |
Why?
| | Absenteeism | 1 | 2024 | 48 | 0.210 |
Why?
| | beta-Lactamases | 1 | 2024 | 48 | 0.210 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 66 | 0.210 |
Why?
| | Nasopharynx | 1 | 2023 | 76 | 0.200 |
Why?
| | Quality Improvement | 2 | 2021 | 1163 | 0.200 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 54 | 0.200 |
Why?
| | Family Characteristics | 1 | 2024 | 189 | 0.200 |
Why?
| | Adult | 6 | 2024 | 37631 | 0.190 |
Why?
| | Pneumococcal Vaccines | 1 | 2023 | 142 | 0.190 |
Why?
| | Age Factors | 2 | 2020 | 3284 | 0.180 |
Why?
| | Azithromycin | 1 | 2022 | 95 | 0.180 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.180 |
Why?
| | Sexual Health | 1 | 2022 | 58 | 0.180 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 169 | 0.180 |
Why?
| | Academic Medical Centers | 1 | 2024 | 504 | 0.180 |
Why?
| | Urban Health | 1 | 2021 | 92 | 0.170 |
Why?
| | Focus Groups | 1 | 2023 | 515 | 0.170 |
Why?
| | Schools | 1 | 2024 | 461 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1462 | 0.170 |
Why?
| | Text Messaging | 1 | 2022 | 156 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5106 | 0.170 |
Why?
| | Decision Support Techniques | 1 | 2024 | 418 | 0.170 |
Why?
| | Private Sector | 1 | 2020 | 52 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2021 | 184 | 0.160 |
Why?
| | Drug Utilization | 1 | 2020 | 169 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 319 | 0.150 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 18 | 0.150 |
Why?
| | Babesia | 1 | 2017 | 3 | 0.140 |
Why?
| | Insurance, Health | 1 | 2020 | 280 | 0.140 |
Why?
| | Tick Bites | 1 | 2017 | 6 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2021 | 951 | 0.140 |
Why?
| | Family Practice | 1 | 2021 | 462 | 0.140 |
Why?
| | Lung Diseases, Fungal | 1 | 2017 | 13 | 0.130 |
Why?
| | Physician Assistants | 1 | 2018 | 92 | 0.130 |
Why?
| | Pediatricians | 1 | 2018 | 129 | 0.130 |
Why?
| | Physicians, Family | 1 | 2018 | 201 | 0.130 |
Why?
| | Case-Control Studies | 1 | 2024 | 3539 | 0.130 |
Why?
| | Public Health | 1 | 2022 | 579 | 0.130 |
Why?
| | Bacteria | 1 | 2023 | 854 | 0.130 |
Why?
| | Interviews as Topic | 1 | 2020 | 772 | 0.130 |
Why?
| | Delayed Diagnosis | 1 | 2017 | 91 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2018 | 137 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2017 | 289 | 0.120 |
Why?
| | Internal Medicine | 1 | 2018 | 260 | 0.120 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.120 |
Why?
| | Disease Reservoirs | 1 | 2015 | 21 | 0.120 |
Why?
| | Emergency Medicine | 1 | 2018 | 226 | 0.120 |
Why?
| | Ticks | 1 | 2015 | 25 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3265 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2015 | 136 | 0.110 |
Why?
| | Vaccination | 1 | 2023 | 1377 | 0.110 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.110 |
Why?
| | Pediatrics | 1 | 2021 | 1094 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2017 | 887 | 0.100 |
Why?
| | Seasons | 1 | 2015 | 544 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2792 | 0.090 |
Why?
| | Cohort Studies | 1 | 2021 | 5701 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1935 | 0.080 |
Why?
| | Ecosystem | 1 | 2015 | 594 | 0.080 |
Why?
| | Prospective Studies | 1 | 2022 | 7572 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 2046 | 0.070 |
Why?
| | Middle Aged | 3 | 2024 | 33228 | 0.070 |
Why?
| | Risk Factors | 2 | 2024 | 10325 | 0.070 |
Why?
| | Disease Progression | 1 | 2015 | 2750 | 0.070 |
Why?
| | Aged | 2 | 2017 | 23794 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2018 | 6032 | 0.070 |
Why?
| | Health Promotion | 2 | 2023 | 734 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5423 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7585 | 0.060 |
Why?
| | Hotlines | 1 | 2024 | 32 | 0.050 |
Why?
| | Hospitals, General | 1 | 2024 | 22 | 0.050 |
Why?
| | Demography | 1 | 2024 | 291 | 0.050 |
Why?
| | Sexual Partners | 1 | 2024 | 186 | 0.050 |
Why?
| | Benchmarking | 1 | 2024 | 183 | 0.050 |
Why?
| | Reproductive Health | 1 | 2022 | 90 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 470 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2022 | 484 | 0.040 |
Why?
| | Poverty | 1 | 2021 | 520 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2375 | 0.030 |
Why?
| | Animals | 1 | 2015 | 36847 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 6726 | 0.020 |
Why?
|
|
Frost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|